Associate Professors Paul Timpson and Shane Grey
12 October 2017
Scientists at the Garvan Institute of Medical Research have received $2.6 million from the National Health and Medical Research Council (NHMRC) to carry out their research into pancreatic cancer, type 1 diabetes, lymphoma and genome sequencing. The funding is part of a package of $197 million announced yesterday by Prime Minister Malcolm Turnbull, which included NHMRC Research Fellowships, Development Grants and other grants, but not the 2017 Project Grants.
Two of Garvan’s leading researchers have become NHMRC Senior Research Fellows:
- Associate Professor Shane Grey (Immunology Division) received a Senior Research Fellowship to expand his groundbreaking research into type 1 diabetes and its treatment. A/Prof Grey has a strong interest in the transplantation of islet cells (the insulin-producing cells of the pancreas) as a treatment for type 1 diabetes, and in how inflammation can affect transplantation success.
- For Associate Professor Paul Timpson (Cancer Division), the Senior Research Fellowship will support the development of new approaches to visualising the progression of pancreatic cancer in living animals. A/Prof Timpson’s work has a particular focus on ‘biosensor mice’, which make it possible to watch, in real time, as cancers progress and as they prepare to spread beyond the primary tumour.
In addition, Associate Professor Tim Mercer, with co-investigators A/Prof Marcel Dinger and Professor David Thomas received a Development Grant to take their innovative work on Sequins in genomic sequencing to the next level. Sequins are short stretches of synthetic ‘mirror-image’ DNA that provide researchers with invaluable information about the quality of individual DNA sequencing reactions.
Dr James Wang received an Overseas Early Career Fellowship to conduct postdoctoral research under the guidance of Professor Chris Goodnow (Immunology Division) and Dr Louis Staudt (National Cancer Institute, USA). Dr Wang’s funding, which is for four years, enables him to conduct his research at both the National Cancer Institute and at Garvan. He will work to develop new mouse models of diffuse large B cell lymphoma, which will speed the investigation of new therapeutic approaches to lymphoma.